ReviewVaccines2023
Tracing down the Updates on Dengue Virus-Molecular Biology, Antivirals, and Vaccine Strategies.
Review in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 35 citations in OpenAlex.
- Daily Mosnodenvir as Dengue Prophylaxis in a Controlled Human Infection Model.The New England journal of medicine · 2025Trial
- Viral Dynamic Model-Informed Dose Selection of Mosnodenvir Prophylaxis against DENV-3 in a Controlled Human Infection Model.Clinical pharmacology and therapeutics · 2026Article
- Exploring anti-dengue activity with atomic-weighted vectors, class balancing and machine learning.Molecular diversity · 2026Article
- Molecular Characterization of DENV-1 Isolates From Pakistan Reveals Immunogenic Variability and Antiviral Potential of Phytochemicals Targeting the CprM Region.Journal of tropical medicine · 2026Article
- Identification of multifunctional T-cell peptide epitopes for the development of DNA vaccines against dengue virus.Human vaccines & immunotherapeutics · 2025Article
- A Review of the Changing Global Impact of Arthropod-Borne Virus Diseases and Recent Initiatives from the World Health Organization.Medical science monitor : international medical journal of experimental and clinical research · 2025Review
- Article
- Engineered Nanobodies for early and accurate diagnosis of dengue virus infection.PLoS neglected tropical diseases · 2025Article
- Dengue virus and infertility: effects on reproductive health and outcomes.JBRA assisted reproduction · 2025Review
- Unraveling viral protein-host membrane interaction for dengue and Zika.Biophysical journal · 2025Article
- Insect-Specific Flaviviruses Have Potential Applications as a Scaffold for Pathogenic Flavivirus Vaccines.Vaccines · 2025Review
- Molecular epidemiology of dengue in Southeast Asia (SEA): Protocol of systematic review and meta-analysis.BMJ open · 2025Article
- Review
- Trends and cross-country inequalities in dengue, 1990-2021.PloS one · 2025Article
- The importance of paying attention to the role of lipid-lowering drugs in controlling dengue virus infection.Virology journal · 2024Review
- Dengue fever in hyperglycemic patients: an emerging public health concern demanding eyes on the effective management strategies.Health science reports · 2024Article
- Dengue outbreaks in northern Nigeria: Evaluating the recommended Takeda vaccine and future prevention strategies.World journal of virology · 2024Review
- Trends and insights in dengue virus research globally: a bibliometric analysis (1995-2023).Journal of translational medicine · 2024Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNearly half of the world is at risk of developing dengue infection. Dengue virus is the causative agent behind this public healthcare concern. Millions of dengue cases are reported every year, leading to thousands of deaths. The scientific community is working to develop effective therapeutic strategies in the form of vaccines and antiviral drugs against dengue.
methodsIn this review, a methodological approach has been used to gather data from the past five years to include the latest developments against the dengue virus.
resultsDifferent therapeutics and antiviral targets against the dengue virus are at different stages of development, but none have been approved by the FDA. Moreover, various vaccination strategies have also been discussed, including attenuated virus vaccines, recombinant subunit vaccines, viral vector vaccines, DNA vaccines, nanotechnology, and plant-based vaccines, which are used to develop effective vaccines for the dengue virus. Many dengue vaccines pass the initial phases of evaluation, but only two vaccines have been approved for public use. DENGVAXIA is the only FDA-approved vaccine against all four stereotypes of the dengue virus, but it is licensed for use only in individuals 6-16 years of age with laboratory-confirmed previous dengue infection and living in endemic countries. Takeda is the second vaccine approved for use in the European Union, the United Kingdom, Brazil, Argentina, Indonesia, and Thailand. It produced sustained antibody responses against all four serotypes of dengue virus, regardless of previous exposure and dosing schedule. Other dengue vaccine candidates at different stages of development are TV-003/005, TDENV PIV, V180, and some DNA vaccines.
conclusionThere is a need to put more effort into developing effective vaccines and therapeutics for dengue, as already approved vaccines and therapeutics have limitations. DENGVAXIA is approved for use in children and teenagers who are 6-16 years of age and have confirmed dengue infection, while Takeda is approved for use in certain countries, and it has withdrawn its application for FDA approval.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.